Abstract:Acute promyelocytic leukemia (APL) is a special subtype of acute myelogenous leukemia (AML) which is characterized for a specific translocation between chromosome 15 and 17 [t(15;17)] and the expression of PML/RARα fusion gene. Celecoxib, one of the specific inhibitors of cyclooxygenase-2 (COX-2), has been reported to induce anti-neoplastic activity on many solid human tumor cell lines in recent years. In our study, ATRA resistant APL cell line MR2 cells were used to investigate the effects of celecoxib on hematological malignancy. MR2 cells were treated with celecoxib at different concentration (0, 20, 40, 80, 120 and 160μmol/L). The proliferation of MR2 cells was observed by MTT assay and apoptosis was detected by DNA fragmentation analysis and flow cytometry using Annexin V-FITC/PI staining. Western blot was used to detect the change of caspase-8, -9, -3 and PARP in MR2 cells. The expression of mRNA of fusion gene PML/RARα, COX-2 and survivin, bcl-2/bax, CIAP1 and CIAP2 was assessed by reverse transcription polymerase chain reaction (RT-PCR). Cell cycle analyzed by flow cytometry with PI staining and western blot was used to detect the expression of cell-cycle-regulating proteins. The telomerase activity of MR2 cells was analyzed by PCR-ELISA. The expression of hTERT mRNA and c-myc mRNA was assessed by RT-PCR. MR2 cells viability in presence of celecoxib decreased markedly in a dose- and time- dependent manner. After treated with celecoxib (20-160μmol/L) for 12-48h, the proliferation of MR2 cells were inhibited significantly, in comparison with the control group (P<0.01). 50% growth inhibition (IC50) at 24h and 48h was 80.93μmol/L and 71.72μmol/L, respectively. A DNA ladder pattern of internucleosomal fragmentation was observed. The translocation of phosphatidylserine at the outer surface of the cell plasma membrane could be induced by celecoxib and its level increased following the augmentation of the drug concentration. MR2 cells exposure to 40-160μmol/L celecoxib for 24h caused 9.59%, 24.00%, 36.10% apoptotic cells, which was more than that of the untreated group 2.84% (P<0.01). The expression of survivin mRNA decreased dramatically, while no significant change with PML/RARα and COX-2. Treatment with celecoxib for 24h resulted in the activation of caspase-3 and caspase-9, cleavage of PARP. 40-160μmol/L celecoxib led to cell cycle arrest in G1/S phase, and CyclinD1 and CyclinE decreased, accompanied with up-regulation of P21waf/cip1, P27KIP, P16INK4a. celecoxib could inhibit the telomerase activity of APL cell line, and the inhibition was dose- and time- dependent. The expression of hTERT mRNA and c-myc mRNA were down-regulated by celecoxib in dose- dependent manner. These results indicated that celecoxib could inhibit MR2 cells proliferation by inducing apoptosis, cell cycle arrest and suppression of telomerase activity.

Effects of Celecoxib on the Reversal of Multidrug Resistance in Human Gastric Carcinoma by Downregulation of the Expression and Activity of P-glycoprotein

[Effect of Selective Cyclooxygenase-2 Inhibitor Celebrex on Expression of Vascular Endothelial Growth Factor (VEGF) in Pancreatic Carcinoma].

Expression of COX-2 in Primary Ovarian Carcinoma and the Effects of Celecoxib on the Cell Proliferation of the Human Ovarian Carcinoma Cell Line A2780

Apoptosis Induced by Celecoxib Eombinated with Cisplatin in Human Osteosarcoma Cell Line MG-63 Via Down-Regulation of PI3K/Akt

Cyclo-Oxygenase 2 Up-Regulates the Effect of Multidrug Resistance

Effect of celecoxib on hepatic and renal functions in rats with mammary carcinoma

Study on the Mechanism of Celecoxib Inhibiting Growth and Inducing Apoptosis of Human Gastric Cancer Cell Line SGC-7901

Effects of a selective cyclooxygenase 2 inhibitor celecoxib on the proliferation and apoptosis of human prostate cancer cell line PC-3]

Effect of Celecoxib on Proliferation, Moving and Invasiveness of Glioma Cells

Celecoxib Enhances Anticancer Effect of Cisplatin and Induces Anoikis in Osteosarcoma Via PI3K/Akt Pathway.

Effects of cyclooxygenase-2 inhibitor celecoxib on cyclooxygenase-2 gene expression and cisplatin chemosensitivity in human lung adenocarcinoma A549 cell line

Effects of Celecoxib on Human Acute Promyelocytic Leukemia Cell Line and Its Mechanism

Efficacy and Safety Profile of Celecoxib for Treating Advanced Cancers: A Meta-Analysis of 11 Randomized Clinical Trials

Characterization of intact antibody-drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography-mass spectrometry.

THE INHIBITORY EFFECT OF CELECOXIB ON LUNG CANCER CELL LINE IN VITRO

[Short-Term Preoperative Treatment of Celecoxib, a Selective Cyclooxygenase-2 Inhibitor, on E-cadherin Expression in Gastric Carcinoma Tissues].

Antioxidative activity and antidiscoloration efficacy of ergothioneine in mushroom (Flammulina velutipes) extract added to beef and fish meats.

Assessment of celecoxib pharmacodynamics in pancreatic cancer

Curcumin Reverses Chemoresistance of Human Gastric Cancer Cells by Downregulating the NF-κB Transcription Factor

ADT-OH Synergistically Enhanced the Antitumor Activity of Celecoxib in Human Colorectal Cancer Cells.

The Molecular Mechanisms of Celecoxib in Tumor Development